Abstract This large community-based cohort study investigates the impact of glucagon-like peptide-1 receptor agonists (GLP-1 RAs), specifically Liraglutide and Semaglutide, on the risk of developing psychiatric conditions such as depression, anxiety, and suicidal behaviors in patients with obesity
O estudo clnico fase II "Retatrutide, a GIP, GLP-1 and glucagon receptor agonist, for people with type 2 diabetes", publicado em junho de 2023 no The Lancet, avaliou a eficcia e a segurana da medicao em 281 pacientes com diabetes tipo 2 e sobrepeso ou obesidade durante 36 semanas de tratamento
PraderWilli syndrome (PWS), a rare genetic disorder, is characterized by hyperphagia
But there are clear signs that can help you tell the difference between a reputable provider and a potential scam
Effects of glucagon-like peptide 1 on counterregulatory hormone responses, cognitive functions, and insulin secretion during hyperinsulinemic, stepped hypoglycemic clamp experiments in healthy volunteers
New Science Suggests Semaglutide Improves CV Outcomes Beyond Weight Loss Semaglutide, the popular anti-obesity medication originally developed to treat diabetes, continues to show cardiovascular benefits beyond weight loss, including reducing risk of death, reducing serious COVID-19-related events and improving heart failure (HF) symptoms, according to six new substudies published in JACC